Cochrane · systematic review · CD003407
Erythropoietin or darbepoetin for patients with cancer
Tonia, T, Mettler, A, Robert, N, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 2 · 33.3%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Erythropoietin or Darbepoetin for patients with cancer
Population: patients with cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 1.05 [1, 1.11] | 78 studies · 19003 participants | High |
On‐study mortality Death occurring up to 30 days after active study protocol | HR 1.17 [1.06, 1.29] | 70 studies · 15935 participants | High |
Thrombotic events | RR 1.52 [1.33, 1.73] | 57 studies · 15278 participants | Moderate Downgraded: publication bias |
Quality of Life ‐ Change in FACT‐Fatigue (13 items) FACT‐F 13 sub‐scale | no estimate extracted | 18 studies · 4965 participants | Low Downgraded: publication bias |
Quality of Life ‐ Change in FACT‐Anaemia (20 items) FACT‐An 20 | no estimate extracted | 6 studies · 1085 participants | Low Downgraded: publication bias |
Participants receiving red blood cell transfusions | RR 0.65 [0.62, 0.68] | 70 studies · 15877 participants | Moderate Downgraded: publication bias |